The role of extracellular adenosine generation in the development of autoimmune diseases

F. Morandi, A. L. Horenstein, R. Rizzo, F. Malavasi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Adenosine (ADO) is an immunosuppressive molecule, which suppresses the immune responses by interacting with specific receptors expressed by immune effector cells. ADO is produced from ATP through the enzymatic activities of CD39 and CD73. Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73. The role of ADO in immunity has been characterized in the last years in physiology and in pathological settings. This review examines a panel of reports focused on the functions of ADO in the context of human autoimmune/inflammatory diseases and the selected animal models. The final aim is to consider the role of adenosinergic ectoenzymes and ADO receptors as novel therapeutic targets for selected diseases.

Original languageEnglish
Article number7019398
JournalMediators of Inflammation
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Adenosine
Autoimmune Diseases
Purinergic P1 Receptors
Immunosuppressive Agents
NAD
Immunity
Animal Models
Adenosine Triphosphate
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

The role of extracellular adenosine generation in the development of autoimmune diseases. / Morandi, F.; Horenstein, A. L.; Rizzo, R.; Malavasi, F.

In: Mediators of Inflammation, Vol. 2018, 7019398, 01.01.2018.

Research output: Contribution to journalReview article

@article{1f4db90ddd0e4c36bbbe022d06cfb585,
title = "The role of extracellular adenosine generation in the development of autoimmune diseases",
abstract = "Adenosine (ADO) is an immunosuppressive molecule, which suppresses the immune responses by interacting with specific receptors expressed by immune effector cells. ADO is produced from ATP through the enzymatic activities of CD39 and CD73. Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73. The role of ADO in immunity has been characterized in the last years in physiology and in pathological settings. This review examines a panel of reports focused on the functions of ADO in the context of human autoimmune/inflammatory diseases and the selected animal models. The final aim is to consider the role of adenosinergic ectoenzymes and ADO receptors as novel therapeutic targets for selected diseases.",
author = "F. Morandi and Horenstein, {A. L.} and R. Rizzo and F. Malavasi",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/7019398",
language = "English",
volume = "2018",
journal = "Mediators of Inflammation",
issn = "0962-9351",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The role of extracellular adenosine generation in the development of autoimmune diseases

AU - Morandi, F.

AU - Horenstein, A. L.

AU - Rizzo, R.

AU - Malavasi, F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Adenosine (ADO) is an immunosuppressive molecule, which suppresses the immune responses by interacting with specific receptors expressed by immune effector cells. ADO is produced from ATP through the enzymatic activities of CD39 and CD73. Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73. The role of ADO in immunity has been characterized in the last years in physiology and in pathological settings. This review examines a panel of reports focused on the functions of ADO in the context of human autoimmune/inflammatory diseases and the selected animal models. The final aim is to consider the role of adenosinergic ectoenzymes and ADO receptors as novel therapeutic targets for selected diseases.

AB - Adenosine (ADO) is an immunosuppressive molecule, which suppresses the immune responses by interacting with specific receptors expressed by immune effector cells. ADO is produced from ATP through the enzymatic activities of CD39 and CD73. Alternatively, ADO can be generated starting from NAD+, which is metabolized by the concerted action of CD38, CD203a/PC-1, and CD73. The role of ADO in immunity has been characterized in the last years in physiology and in pathological settings. This review examines a panel of reports focused on the functions of ADO in the context of human autoimmune/inflammatory diseases and the selected animal models. The final aim is to consider the role of adenosinergic ectoenzymes and ADO receptors as novel therapeutic targets for selected diseases.

UR - http://www.scopus.com/inward/record.url?scp=85050652253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050652253&partnerID=8YFLogxK

U2 - 10.1155/2018/7019398

DO - 10.1155/2018/7019398

M3 - Review article

C2 - 29769837

AN - SCOPUS:85050652253

VL - 2018

JO - Mediators of Inflammation

JF - Mediators of Inflammation

SN - 0962-9351

M1 - 7019398

ER -